Biomerieux falls to two-week low on Q3 miss, FY sales guidance cut

Biomerieux SA

04/11/2025 08:11

** Shares in French Biomerieux BIOX.PA fall around 3%, to their lowest since mid-October, after the medical supplier missed Q3 sales expectations, and cut its full-year sales growth target

** The company says it now expects annual revenues to grow by between 5.5%-6.5%, against 6%-7.5% guided earlier

** The firm also reported weaker-than-expected Q3 sales standing at 948 million euros ($1.11 billion), with traders from HSBC expecting the shares to fall 2%-3% due to the miss

** The analysts polled by the company expected the revenues in the quarter to come in at 975 million euros

** Up to the previous session's close, shares were up 7.1%​ YTD

($1 = 0.8575 euros)

 (Reporting by Mateusz Rabiega)

 ((Mateusz.rabiega@thomsonreuters.com))